Literature DB >> 11280075

Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines.

Z Babaloo1, P M Kaye, M B Eslami.   

Abstract

The role of interleukin (IL)-13, a Th2 cytokine sharing many of the features of IL-4, has not previously been examined in patients with visceral leishmaniasis (VL). We examined sera from Iranian patients with VL caused by Leishmania infantum. Serum IL-13 was detected in 50% (22/44) of patients with active primary disease. In comparison, IL-10 was detected in 79.5% (35/44), interferon gamma (IFN gamma) in 38.5% (17/44), and IL-4 in only 5% (2/44) of these patients. With few exceptions all 3 cytokines were undetectable after clinical recovery following antimony therapy. Five of 7 patients (71%) who failed antimony therapy and had relapsing disease had similar levels of IL-10 to patients with active primary disease. However, with only 1 exception, IL-13, IFN gamma and IL-4 were not detected in such patients. These data suggest that relapsing disease may result from defective cellular immunity, unrelated to immunosuppression mediated by IL-10.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280075     DOI: 10.1016/s0035-9203(01)90344-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  19 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  IL-18 stimulates IL-13-mediated IFN-gamma-sensitive host resistance in vivo.

Authors:  Qian Liu; Zhugong Liu; Jeannette Whitmire; Farhang Alem; Hossein Hamed; John Pesce; Joseph F Urban; William C Gause
Journal:  Eur J Immunol       Date:  2006-05       Impact factor: 5.532

4.  Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Authors:  Mona E E Elfaki; Eltahir A G Khalil; Anne S De Groot; Ahmed M Musa; Andres Gutierrez; Brima M Younis; Kawthar A M Salih; Ahmed M El-Hassan
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

5.  Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.

Authors:  Henry W Murray; Christina M Lu; Smita Mauze; Sherry Freeman; Andre L Moreira; Gilla Kaplan; Robert L Coffman
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

Review 6.  Tissue granuloma structure-function in experimental visceral leishmaniasis.

Authors:  H W Murray
Journal:  Int J Exp Pathol       Date:  2001-10       Impact factor: 1.925

7.  Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity.

Authors:  Simona Stäger; James Alexander; K Christine Carter; Frank Brombacher; Paul M Kaye
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

8.  Aeroallergens Exacerbate Histoplasma capsulatum Infection.

Authors:  Chelsea L Bueter; George S Deepe
Journal:  J Immunol       Date:  2018-10-22       Impact factor: 5.422

Review 9.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

10.  Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression.

Authors:  E Yaneth Osorio; Weiguo Zhao; Claudia Espitia; Omar Saldarriaga; Leo Hawel; Craig V Byus; Bruno L Travi; Peter C Melby
Journal:  PLoS Pathog       Date:  2012-01-19       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.